MedTrace Logo

Safety and Toleration of PEP005 Topical Gel When Applied to a Treatment Area of up to 100cm2

NCT00659893 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 64

Last updated 2015-09-14

No results posted yet for this study

Summary

Study Hypothesis: Safety and Tolerability will differ when treating multiple contiguous 25 cm2 treatment areas, as compared to individual 25 cm2 treatment areas.

Conditions

  • Actinic Keratosis

Interventions

DRUG

PEP005 Topical gel

0.05%, two day dose

Sponsors & Collaborators

  • Peplin

    lead INDUSTRY

Principal Investigators

  • George Schmieder, DO · Park Avenue Dermatology

  • Stephen Shumack, MD · St George Dermatology and Skin and Cancer Centre

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
FACTORIAL

Eligibility

Min Age
18 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-04-30
Primary Completion
2008-11-30
Completion
2008-11-30

Countries

  • United States
  • Australia

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00659893 on ClinicalTrials.gov